TerrAscend (TSNDF) Income from Non-Controlling Interests (2021 - 2026)
TerrAscend (TSNDF) reported Income from Non-Controlling Interests of $1.1 million for Q1 2026, down 18.89% year-over-year from $1.3 million in Q1 2025, and down 5.04% quarter-over-quarter from $1.1 million in Q4 2025.
TerrAscend (TSNDF) Income from Non-Controlling Interests (2021 - 2026) Analysis & Trends
TerrAscend (TSNDF) has 6 years of Income from Non-Controlling Interests data on file, last reported at $1.1 million in Q1 2026.
- Income from Non-Controlling Interests for Q1 2026 came in at $1.1 million, down 18.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.7 million (down 30.17% YoY), and the FY2025 annual result was $4.9 million, down 35.24% from the prior year.
- Income from Non-Controlling Interests retreated to $1.1 million in Q1 2026 per TSNDF's latest filing, from $1.1 million in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $2.3 million in Q4 2023 and troughed at $351000.0 in Q1 2022.
- A 5-year average of $1.6 million and a median of $1.7 million in 2024 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2023 and 2025: Income from Non-Controlling Interests surged 522.79% in 2023, then slumped 40.93% in 2025.
- A 5-year view of Income from Non-Controlling Interests shows it stood at $1.0 million in 2022, then jumped by 124.66% to $2.3 million in 2023, then dropped by 27.42% to $1.7 million in 2024, then sank by 34.05% to $1.1 million in 2025, then slipped by 5.04% to $1.1 million in 2026.
- Business Quant data shows TSNDF's Income from Non-Controlling Interests at $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $1.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 22.56 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | TerrAscend | - | - | 34.60 Mn | 1.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.06 Mn |
| Dec 31, 2025 | 1.11 Mn |
| Sep 30, 2025 | 1.21 Mn |
| Jun 30, 2025 | 1.28 Mn |
| Mar 31, 2025 | 1.30 Mn |
| Dec 31, 2024 | 1.69 Mn |
| Sep 30, 2024 | 1.73 Mn |
| Jun 30, 2024 | 1.94 Mn |
| Mar 31, 2024 | 2.20 Mn |
| Dec 31, 2023 | 2.32 Mn |
| Sep 30, 2023 | 2.16 Mn |
| Jun 30, 2023 | 2.14 Mn |
| Mar 31, 2023 | 2.19 Mn |
| Dec 31, 2022 | 1.03 Mn |
| Sep 30, 2022 | 2.23 Mn |
| Jun 30, 2022 | 945,000.00 |
| Mar 31, 2022 | 351,000.00 |
| Dec 31, 2021 | 556,000.00 |
| Sep 30, 2021 | 1.41 Mn |
| Jun 30, 2021 | 998,000.00 |